Stella E Lee

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

C. Bachert, W. Fokkens, J. Mullol, 2019, The Lancet.

Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

E. Kerwin, S. Yancey, W. Fokkens, 2023, Journal of Patient-Reported Outcomes.

Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.

C. Bachert, G. Canonica, P. Hellings, 2021, Rhinology.